

Endowment Fund Name: Boehringer Ingelheim Biotherapeutic Safety Excellence Fund

Sponsoring Specialty Section: Biotechnology Specialty Section

Purpose: The goal of the Boehringer Ingelheim Biotherapeutic Safety Excellence Fund is to encourage research and training of students and postdoctoral fellows in nonclinical safety sciences as applied to the biotherapeutic products. Proceeds from the fund will be used for annual grants to graduate students and/or postdoctoral fellows whose research is aligned with the above-stated purpose of the Fund and who have demonstrated excellence in toxicological research advancing the understanding of biotherapeutic safety.

Management: The Biotechnology Specialty Section shall determine each year the gross amount to be awarded from the Fund. Annually, the number of awards and the identification of the award recipients shall be the responsibility of an Award Management Committee to be appointed by the Biotechnology Specialty Section. The award or awards, to be known as the “Boehringer Ingelheim Award for Excellence in Biotherapeutic Safety” shall be presented at the Annual Meeting of the Society of Toxicology.

Background: Research and development of biotherapeutic medicines present challenges to assessment of their safety in the nonclinical setting. The discipline of toxicology must adapt safety assessment methodologies to these new therapeutic modalities, which requires that research in this area of science be encouraged. Boehringer Ingelheim aims to contribute to advancing this science through the awards made possible by this fund.

Funding: Initial funding will be provided by a gift of \$25,000 from Boehringer Ingelheim Pharmaceuticals, Inc. It is anticipated that this gift will be matched by a gift from SOT, to be approved by Council, thereby establishing the fund as a Permanently Restricted Fund. Should the fund not reach \$50,000 within three years from the initial gift, the fund will become a Temporary Restricted Fund, to be completely distributed over a period of years specified by the Endowment Board.

Leadership for Fundraising: It is expected that a Fundraising Committee will be appointed by the Specialty Section to engage in fundraising activities to increase the size of the fund.

Termination: In the unlikely event that the Biotechnology Specialty Section should cease to exist or if it should no longer wish to be aligned with the Fund, the SOT Endowment Board shall recommend to SOT Council for ratification the transfer of the remaining assets of the Fund to a new or existing fund having a purpose or purposes consistent with those of the Fund.

Approved by the Endowment Fund Board: March 15, 2016

Ratified by Council: May 17, 2016